Nicolai Tangen meets with David Ricks, CEO of Eli Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is Eli Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original purpose - from treating addiction to potentially impacting Alzheimer's. Ricks reveals how the company has revolutionized drug development by cutting traditional timelines in half, how it navigates global market challenges, and how it approaches drug pricing and innovation. A must-listen for anyone curious about the future of medicine!
In Good Company is hosted by Nicolai Tangen, CEO of Norges Bank Investment Management. New full episodes every Wednesday, and don't miss our Highlight episodes every Friday.
The production team for this episode includes Isabelle Karlsson and PLAN-B's Niklas Figenschau Johansen, Sebastian Langvik-Hansen and Pål Huuse. Background research was conducted by Kristian Haga.
Hosted on Acast. See acast.com/privacy for more information.
